Related Experiment Video

Updated: Jan 5, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies

Monika Toma1,2, Katherine Sullivan-Reed3, Tomasz Śliwiński4

  • 1Sol Sherry Thrombosis Research Center and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA. monikatoma3@gmail.com.

Cancers
|October 17, 2019
PubMed

Insights

Targeting DNA repair pathways offers cancer treatment opportunities. Simultaneous inhibition of RAD52 and PARP1 may create synthetic lethality to eradicate BRCA1/2-deficient tumors, overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer development involves DNA repair system alterations.
  • Synthetic lethality exploits cancer-specific DNA repair defects for targeted therapy.
  • PARP1 inhibition is effective against BRCA1/2-deficient tumors but faces resistance.

Purpose of the Study:

  • To explore RAD52 as a therapeutic target in cancer treatment.
  • To investigate the potential of dual synthetic lethality targeting RAD52 and PARP1.
  • To address treatment resistance in BRCA1/2-deficient tumors.

Main Methods:

  • Review of DNA repair mechanisms, including homologous recombination (HR).
  • Analysis of synthetic lethal interactions involving BRCA1/2, PARP1, and RAD52.
  • Discussion of therapeutic strategies for targeting DNA repair pathways.

Main Results:

  • BRCA1/2-deficient tumors are susceptible to PARP1 inhibition.
  • RAD52-mediated HR can confer resistance to PARP1 inhibitors.
  • Simultaneous inhibition of RAD52 and PARP1 shows potential for enhanced synthetic lethality.

Conclusions:

  • RAD52 inhibition could overcome resistance to PARP1 inhibitors in BRCA1/2-deficient cancers.
  • Dual targeting of RAD52 and PARP1 presents a promising strategy for robust synthetic lethality.
  • This approach may lead to more effective eradication of BRCA1/2-deficient tumors.
Keywords:
DNA repairPARP1RAD52dual synthetic lethalitysynthetic lethality

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K